Dividend Growth of Amgen Inc.(AMGN)

Amgen (AMGN) is having a Dividend Yield of 2.68% with the Annual cash Dividend per share of $4. The last quarter cash dividend per share pay out was $1. Amgen has a 5 year average dividend yield of 1.99% and the stock has a Indicated annual dividend of $4.6. Amgen (AMGN) formally announced its most recent dividend on December 21, 2016 with a Dividend per share of $1.15. The new indicated annual dividend based on announced dividend per share is $4.6. The dividend yield based on the forward looking indicated annual dividend is 2.68%. Amgen (AMGN) has the most recent dividend payout ratio of 0.34 with a 5-year average payout ratio of 0.3. Companys change in pay out ratio when compared to the last 5 years average pay out ratio has been 0.05. The 5 year historical dividend growth of Amgen (AMGN) is at the rate of 27.97% while the R-Squared dividend growth is 0.96. If the value of R-Square is close to one, it indicates a perfect fit and the higher value conforms to the regression line while data close to zero indicates the opposite.

Amgen Inc. (NASDAQ:AMGN) rose 0.19% or 0.32 points on Thursday and made its way into the gainers of the day. After trading began at $171.56 the stock was seen hitting $172.17 as a peak level and $170.3001 as the lowest level. The stock ended up at $172.11. The daily volume was measured at 2,660,644 shares. The 52-week high of the share price is $176.85 and the 52-week low is $133.64. The company has a market cap of $126,751 million. Shares of Amgen Inc. rose by 3.48% in the last five trading days and 11.25% for the last 4 weeks. Amgen Inc. is up 17.84% in the last 3-month period. Year-to-Date the stock performance stands at 18.53%.

Currently the company Insiders own 0.2% of Amgen Inc. shares according to the proxy statements. Institutional Investors own 79.04% of Amgen Inc. shares. Company has reported several Insider transactions to the SEC, on Aug 3, 2016, Annette Louise Such (VP, Finance and CAO) sold 3,000 shares at 174.59 per share price.On May 5, 2016, Madhavan Balachandran (EVP, Operations) sold 30,000 shares at 154.12 per share price.On May 3, 2016, Sean E Harper (EVP, Research & Development) sold 21,875 shares at 157.99 per share price.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Amgen was Upgraded by BofA/Merrill to Buy on Feb 1, 2017. Amgen was Downgraded by Credit Suisse to Neutral on Dec 20, 2016. Amgen was Initiated by Oppenheimer to Outperform on Dec 13, 2016.

Amgen Last issued its quarterly earnings results on Feb 2, 2017. The company reported $2.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.10. Analyst had a consensus of $2.79. The company had revenue of $5965.00 million for the quarter, compared to analysts expectations of $5750.58 million. The companys revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.61 EPS.

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new sciences promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve peoples lives.

Amgen

Post Comment

*